Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study).
Hwang K, Kim TM, Park CK, Chang JH, Jung TY, Kim JH, Nam DH, Kim SH, Yoo H, Hong YK, Kim EY, Lee DE, Joo J, Kim YJ, Choe G, Choi BS, Kang SG, Kim JH, Kim CY.
Hwang K, et al. Among authors: nam dh.
Cancer Res Treat. 2020 Apr;52(2):505-515. doi: 10.4143/crt.2019.421. Epub 2019 Oct 28.
Cancer Res Treat. 2020.
PMID: 31671938
Free PMC article.
Clinical Trial.